From Seekingalpha · Lane Simonian · · 40s
AriBio Phase 3 Results for Alzheimer's Drug
AriBio's Alzheimer's drug AR1001 nears phase 3 results with Fosun Pharmaceuticals.
In brief
AriBio's Alzheimer's drug AR1001 nears phase 3 results with Fosun Pharmaceuticals. AriBio's AR1001 drug for Alzheimer's disease is set to show phase 3 trial results within a month, but investors are cautious due to Alzheimer's drug development risks. Originally reported by Seekingalpha.
AriBio Phase 3 Trial
AriBio is set to announce phase 3 trial results for AR1001 within a month.
“AR1001 likely works better than any current drug approved for Alzheimer's disease”
Fosun Pharmaceuticals Deal
Shanghai Fosun Pharmaceuticals secured regional rights to AR1001 via a $60M option fee.
Fosun Financials
Fosun has $5.8B in revenues and $485M in profits but high R&D costs.
Investor Recommendation
Investor does not recommend SFOSF due to OTC status and Alzheimer's drug risks.
The takeaway
AriBio's AR1001 drug for Alzheimer's disease is set to show phase 3 trial results within a month, but investors are cautious due to Alzheimer's drug development risks.
